Stakeholder Engagement

Together with our stakeholders, we target unmet needs to support patients across the globe.

abbvie-man-woman-meeting@2x

Taking on the Most Complex Health Challenges

Our collaboration with peers, academics and clinical experts is helping address the industry’s biggest challenges and improve patient health across the globe. For example, in Europe, we’re finding solutions to improve patient care while reducing costs by bringing together academia, healthcare providers, patients’ groups and industry through our Sustainable Healthcare initiative. The AbbVie Foundation also partners with many organizations to strengthen health systems, education and communities around the world.

abbvie-video-innovativeresearch
See how we’re solving the world's most difficult health challenges, including neglected tropical diseases (NTDs), through the pro bono work of scientists, partnerships with organizations like Medicines for Malaria Venture and grants from the AbbVie Foundation.

Solving Neglected Diseases

We work to address NTDs that disproportionately impact the world’s poor and marginalized populations. More than 160 of AbbVie’s most experienced scientists are collaborating with partners on drug development projects, advisory boards and compound screening to help solve NTDs.

In addition, we provide a large library of diverse chemicals to screen against many NTDs. Our Executive Council on Neglected Diseases coordinates efforts across the company to contribute innovative technologies, compounds for screening and our scientific expertise.

Our NTD Partners

Drugs for Neglected Diseases initiative (DNDi)

DNDi is a nonprofit drug research and development organization that is developing new treatments for neglected diseases. Our partnership supplies thousands of our compounds to be screened for activity against leishmania, Chagas disease and helminth infections. Our relationship expanded in 2012 to include a four-year joint research and nonexclusive licensing agreement. This provides DNDi access to selected classes of AbbVie’s proprietary molecules, identified from the above screens, and accompanying data to guide the search for improved treatments. Any products developed as a result of this partnership are provided to endemic countries by DNDi at the lowest sustainable price to ensure the greatest patient access

Gates Foundation TB Drug Accelerator (TBDA) consortium

As a founding member of TBDA, AbbVie has provided over 100,000 of our compounds for screening against replicating tuberculosis (TB). Active compounds from these screens are shared within the consortium to speed the identification of the most promising approaches to shorten and improve the quality of TB therapy. Our scientists are very engaged with this partnership, providing cheminformatics support and characterizing lead compounds from other TBDA partners in addition to the above screening activities.

TB Alliance

AbbVie scientists provide technical consulting through the TB Alliance Scientific Advisory Council, while new compounds are synthesized at AbbVie and then screened against both replicating and latent TB at the University of Illinois, Chicago.

Medicines for Malaria Venture (MMV)

AbbVie is working closely with MMV to support two preclinical development programs of novel antimalarials.

University partnerships

We work with leading research institutions, including Liverpool School of Tropical Medicine (Anti-Wolbachia Consortium), University of Washington, University of Sussex and University of Dundee (Drug Discovery Unit) on NTD screening and research. In addition, we provide laboratory facilities and mentor student interns under a program sponsored by Franciscan University of Steubenville (Franciscan Institute for World Health).

Government partnerships

Through our sponsorship of the Brazilian Scientific Mobility program, AbbVie employees mentor students, sharing their expertise with the next generation of innovators. The program grants Brazilian students opportunities to study STEM fields in the United States and promotes knowledge sharing and capacity building by investing in future leaders.

In Argentina, AbbVie has partnered with the Ministry of Health of Jujuy since 2012.

AbbVie Foundation treating NTDs

The AbbVie Foundation, a nonprofit charitable organization, supports advancing progress against NTDs. Its grants support organizations including the University of Notre Dame and MAP International, helps prevent and treat NTDs in Bolivia, the Ivory Coast and Haiti. In the Ivory Coast, a three-year partnership with MAP International is helping to treat Buruli ulcer (a severe skin ulceration) through education campaigns, health care professional training and treatment.

8,000 number of health workers who delivered Mass Drug Administration to more than 2 million people in Haiti at the end of 2013

99% of people with Buruli ulcer who are treated completed the full antibiotic treatment needed in the Ivory Coast

13,500 hours of expertise contributed by more than 100 of AbbVie’s most experienced scientists in 2014 to helping solve NTDs

Industry Collaboration to Combat Neglected Diseases

In a new, coordinated campaign to eliminate or control 10 NTDs by the year 2020, we joined a coalition of partners that includes 12 other health care companies, the Bill & Melinda Gates Foundation, World Bank, several leading non-governmental organizations and the governments of several large countries. In the largest coordinated effort to date to combat NTDs, AbbVie and the coalition partners will collectively sustain or expand existing medicine donation programs. We will also further share expertise and compounds to accelerate the development of new medicines and strengthen medicine distribution programs. Learn more about AbbVie’s support for the London Declaration on NTDs.